Appili Therapeutics Inc Class A (APLI.H) AI Stock Analysis

27 Followers

Appili Therapeutics Inc Class A

(TSXV:APLI.H)

Select Model

Rating:42Neutral

Price Target:CAD 0.01▲(0.00% Upside)

Action:reiterated

Date:09/25/26

The overall score is low primarily because of very weak financial performance, including persistent losses, negative equity, rising debt, and continued cash burn that signal high balance-sheet and funding risk. Secondarily, technical indicators show a price trading below key moving averages with neutral-to-soft momentum, reinforcing a cautious near-term view. Valuation metrics offer little support, with a negative P/E and no dividend yield information, leaving limited evidence of fundamental or income-based appeal at current levels.

Positive Factors

Reported Revenue GrowthThe reported revenue growth rate indicates that the company has expanded its current revenue base materially. If supported by continued development progress and customer or partner activity, this growth can improve operating leverage and strengthen the commercial foundation over the next several quarters.

Negative Factors

Severely Stressed Balance SheetNegative equity and debt that materially exceeds the asset base indicate very limited financial flexibility. This structure can constrain investment in clinical programs, increase refinancing dependence, and raise the likelihood that future funding could dilute existing shareholders.

Appili Therapeutics Inc Class A (APLI.H) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 264.73K
Dividend Yield: ―
Average Volume (3M): 86.14K
Price to Earnings (P/E): -0.1
Beta (1Y): -0.69
Revenue Growth: 43.44%
EPS Growth: -101.92%
Country: Canada
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company Description

Appili Therapeutics, Inc. is a biopharmaceutical company, which engages in acquisition and development of novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective program...

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Appili’s ability to generate recurring product sales depends on successfully developing and commercializing drug candidates; specific, current commercial product revenue details are not available in the...

Appili Therapeutics Inc Class A Financial Statement Overview

Summary

Financial performance is very weak: revenue remains tiny despite some recent improvement, gross margins are near 100% but operating and net losses are many times larger than sales, cash burn is high with largely negative operating and free cash flow, and shareholders’ equity is deeply negative with rising debt, indicating a highly stressed balance sheet and elevated financing risk.

Income Statement

33Negative

Balance Sheet

9Very Negative

Cash Flow

21Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	378.81K	244.18K	100.44K	827.41K	334.18K	1.39M
Gross Profit	372.99K	236.09K	100.44K	827.41K	327.91K	1.39M
EBITDA	-5.86M	-6.53M	360.57K	-2.07M	-8.10M	-23.51M
Net Income	-4.68M	-4.24M	-2.62M	-3.78M	-9.24M	-25.12M
Balance Sheet
Total Assets	1.30M	1.97M	3.03M	1.49M	3.13M	8.28M
Cash, Cash Equivalents and Short-Term Investments	138.68K	40.00K	1.23M	94.49K	2.47M	6.66M
Total Debt	13.33M	12.94M	12.29M	8.18M	7.67M	4.98M
Total Liabilities	20.32M	19.30M	16.43M	12.42M	10.53M	11.55M
Stockholders Equity	-19.02M	-17.33M	-13.40M	-10.92M	-7.40M	-3.27M
Cash Flow
Free Cash Flow	-1.32M	-1.38M	866.46K	-2.49M	-10.10M	-19.08M
Operating Cash Flow	-1.35M	-1.38M	868.82K	-2.46M	-10.10M	-19.08M
Investing Cash Flow	0	0	-2,360	-29.06K	-3,175	5.06M
Financing Cash Flow	350.30K	197.82K	193.68K	122.05K	5.91M	9.56M

Appili Therapeutics Inc Class A Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.01Negative

100DMA0.02Negative

200DMA0.02Negative

Market Momentum

MACD-0.00Negative

RSI45.90Neutral

STOCH16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI.H, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APLI.H.

Appili Therapeutics Inc Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:APLI.H against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:MIR	47Neutral	CAD 31.58M	-7.95	12.68%	―	45.72%	35.82%
TSE:APLI.H	42Neutral	CAD 661.83K	-0.14	27.40%	―	43.44%	-101.92%
TSE:KNE	40Underperform	CAD 6.15M	-2.05	273.53%	―	―	―
TSE:VXL	37Underperform	CAD 438.24K	1.15	34.52%	―	―	―
TSE:BIOV	29Underperform	CAD 2.04M	-0.35	149.46%	―	―	―

* Healthcare Sector Average

Performance Comparison

TSE:APLI.H and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:APLI.H	Appili Therapeutics Inc Class A	0.01	-0.01	-50.00%
TSE:KNE	Kane Biotech	0.03	-0.01	-25.00%
TSE:MIR	Medmira Inc	0.04	-0.04	-50.00%
TSE:VXL	Vaxil Bio	0.11	-0.06	-35.29%
TSE:BIOV	Biovaxys Technology Corp	0.07	-0.17	-71.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 25, 2026

Appili Therapeutics Inc Class A AI Stock Analysis